GlaxoSmithKline builds new paradigm
The business model that has long sustained the research-based pharmaceutical industry is faltering, with the steady stream of blockbuster medications that once characterized it drying up and competition from generics suppliers increasing as an unprecedented number of branded products lose patent pro